# Comparative single-cell landscape of immune cells in human livers affected HBV and non-viral cirrhosis

**Authors:** Qingquan Bai, Zhengyang Zhao, Jiashu Zou, Chenhao Wang, Xiao He, Shuqi Mao, Yongcheng Su, Da Li, Bowen Zheng, Shengdong Wu, Caide Lu, Meiya Chen

PMC · DOI: 10.3389/fmed.2025.1708675 · Frontiers in Medicine · 2026-02-20

## TL;DR

This study compares immune cell differences in livers with HBV and non-viral cirrhosis using single-cell sequencing to identify unique immune patterns and potential treatment targets.

## Contribution

The study reveals distinct immune cell subsets and signaling pathways specific to HBV-induced cirrhosis compared to non-viral cirrhosis.

## Key findings

- HBV cirrhosis shows expanded Macrophage-PLCG2 and CD8+ T-FABP5 immune subsets.
- Reduced Macrophage-CD5L and specific T/NK cell subsets are observed in HBV cirrhosis.
- Enhanced HLA-E/KLRK1 signaling between myeloid and NK cells is linked to HBV cirrhosis.

## Abstract

Cirrhosis, particularly HBV-induced, poses a significant global health burden. This study compares immune cell landscapes in HBV and non-viral cirrhosis using single-cell RNA sequencing (scRNA-seq) to elucidate distinct immune mechanisms driving disease progression.

Liver tissues from HBV cirrhosis patients and healthy controls were analyzed via scRNA-seq. Public single-cell and spatial transcriptomics data were integrated to map immune cell populations. Computational analyses included differential expression, pathway enrichment (KEGG/GO), and cell–cell communication (CellChat).

HBV cirrhosis exhibited expanded Macrophage-PLCG2 (anti-inflammatory) and CD8 + T-FABP5 subsets, while Macrophage-CD5L, CD4 + T-ANXA1, CD4 + T-CCR6, and NK-FCER1G were reduced. Pathway analysis linked Macrophage-PLCG2 to Rap1 signaling, whereas Macrophage-CD5L associated with lysosomal pathways. Spatial analysis revealed myeloid-T cell colocalization in HBV cirrhosis. Enhanced HLA-E/KLRK1 signaling between myeloid and NK cells was identified in HBV cases (p < 0.05).

This study delineates immune cell heterogeneity between HBV and non-viral cirrhosis, highlighting potential therapeutic targets like Macrophage-PLCG2 and CD8 + T-FABP5. Findings underscore the role of immune dysregulation in HBV cirrhosis progression.

## Linked entities

- **Genes:** PLCG2 (phospholipase C gamma 2) [NCBI Gene 5336], FABP5 (fatty acid binding protein 5) [NCBI Gene 2171], CD5L (CD5 molecule like) [NCBI Gene 922], ANXA1 (annexin A1) [NCBI Gene 301], CCR6 (C-C motif chemokine receptor 6) [NCBI Gene 1235], FCER1G (Fc epsilon receptor Ig) [NCBI Gene 2207], HLA-E (major histocompatibility complex, class I, E) [NCBI Gene 3133], KLRK1 (killer cell lectin like receptor K1) [NCBI Gene 22914]
- **Diseases:** cirrhosis (MONDO:0005155)

## Full-text entities

- **Genes:** CD4 (CD4 molecule) [NCBI Gene 920] {aka CD4mut, IMD79, Leu-3, OKT4D, T4}, ANXA1 (annexin A1) [NCBI Gene 301] {aka ANX1, LPC1}, FCER1G (Fc epsilon receptor Ig) [NCBI Gene 2207] {aka FCRG}, CD5L (CD5 molecule like) [NCBI Gene 922] {aka AIM, API6, CT-2, PRO229, SP-ALPHA, Spalpha}, RAP1A (RAP1A, member of RAS oncogene family) [NCBI Gene 5906] {aka C21KG, G-22K, KREV-1, KREV1, RAP1, SMGP21}, HLA-E (major histocompatibility complex, class I, E) [NCBI Gene 3133] {aka HLA-6.2, QA1}, CCR6 (C-C motif chemokine receptor 6) [NCBI Gene 1235] {aka BN-1, C-C CKR-6, CC-CKR-6, CCR-6, CD196, CKR-L3}, PLCG2 (phospholipase C gamma 2) [NCBI Gene 5336] {aka APLAID, FCAS3, PLC-IV, PLC-gamma-2}, KLRK1 (killer cell lectin like receptor K1) [NCBI Gene 22914] {aka CD314, D12S2489E, KLR, NKG2-D, NKG2D}, CD8A (CD8 subunit alpha) [NCBI Gene 925] {aka CD8, CD8alpha, IMD116, Leu2, p32}
- **Diseases:** Cirrhosis (MESH:D005355), inflammatory (MESH:D007249), HBV cirrhosis (MESH:D006509)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12971635/full.md

## Figures

6 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12971635/full.md

## References

42 references — full list in the complete paper: https://tomesphere.com/paper/PMC12971635/full.md

---
Source: https://tomesphere.com/paper/PMC12971635